Biography
Biography: Mewa Singh
Abstract
Over the past decade, there is a common problem to number of drug candidates with solubility problems has steadily increased as a result of using combinatory chemistry and high-throughput screening in drug discovery. Presently, 70% of new entities (therapies and drugs) are poorly soluble and 40% of existing immediate-release oral drugs are considered practically insoluble in water. In the pursuit to achieve optimal concentration this often leads to dose escalation. Dose escalation is often undesirable for the following reasons. (1) Increases toxicity, (2) difficulty in designing formulation, (3) manufacturing and treatment costs increase dramatically, and (4) use of toxic carriers and solubilizing agents is increased.
Paclitaxel is one of them, even after so many years the delivery system is still compromised.
• $4.5 Billion market for Taxol in 2013
• Market is growing.
• Taxol patent has expired.
• Nano-technology has been touted as the “next new thing” for several years but has not been perfected for Taxol yet, until now.
• We are not using “me-too technology” like other Nano-medicine formulations.
• Patents were filed in 2012 and 2013.
• Abraxane is a very successful drug on the market currently (run rate > $1B) using nano technology, not really but micronized.
Meda biotech has developed a nano formulation for this molecule. Paclitaxel is attached with curcumin which is a safe natural molecule from turmeric natural anti-inflammatory molecule. Curcumin also known for controlling many type of cancer cells. The end formulation is nano formulation and has better cytotoxicity than Abraxane. It has better stability in acidic and alkaline environment.
Our double edge approach with improved solubility should be a winner